昊海生物科技(06826.HK)中期纯利跌13.65%至1.83亿元研发费用同比增31.3%
格隆汇8月2日丨昊海生物科技(06826.HK)公布，截至2019年6月30日止中期，实现收入7.81亿元(人民币，单位下同)，同比增长2.57%；毛利5.97亿元，同比减少0.95%；母公司拥有人应占利润1.83亿元，同比减少13.65%；基本及摊薄每股盈利1.14元；不派末期息。
于报告期内，受到医疗美容终端市场阶段性行业整制以及竞品销售价格大幅下降的双重影响，集团玻尿酸产品销售收入及销售单价均有所下降。但受益于玻璃酸钠注射液、人工晶状体和外用重组人表皮生长因子等产品销售收入的持续上升，集团于报告期的总营业收入依然较去年同期有所增长。
于报告期内，集团整体毛利率为76.5%，较2018年同期的79.2%有所下降，主要是由毛利率较高的玻尿酸产品营业收入占比下降所致。
于报告期内，公司普通股权益持有人应占利润同比有所下降，主要影响因素如下：集团加大了对于眼科和医美新产品的研发投入，当期发生的研究开发费用较去年同期增加约人民币1224万元，增幅高达31.3%；公司附属公司Contamac Holdings于2019年1月出售了其在合营企业Contateq的50%股权，产生了一次性投资损失约人民币953万元；Contamac Holdings于2019年4月25日收购了法国人工晶状体推注器生产商ODC的100%股权，考虑到Contamac Holdings与ODC之间的整合周期较长以及该业务未来盈利能力存在一定不确定性，出于谨慎性考虑，管理层於当期对该笔收购确认了非经常性的投资损失约人民币8.06百万元；集团于2018年上半年收到高新技术成果转化项目财政扶持资金约人民币1439万元并记入经常性损益。
此外，集团继续加强研发投入，报告期内，研发费用共计约人民币5132万元，较2018年同期增长31.3%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
